Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Crush
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseCrushPeripheral-nerve crushC57BL/6 wild-type and homozygous RAGE-null micemalen = n=9 per group for myelinated fibre histology; n=15 per grou…Germline knockout; bone marrow reconstitution by intraorbital injection; streptozotocin intraperitonealGenetic deletion, no dose. Streptozotocin 50 mg/kg; lethal…RAGE deletion constitutive and present before injury; bone marrow transplantati…
Model: Unilateral sciatic nerve crush performed 2 months after confirmation of streptozotocin-induced type 1 diabetes (streptozotocin 50 mg/kg intraperitoneally for 5 days; blood glucose above 13 mmol/L defined as diabetic)
RAGE deletion, global or restricted to bone marrow, increased myelinated fibre density and motor and sensory conduction velocity after sciatic nerve crush in diabetic mice, with greater M2 macrophage polarisation; no significant benefit was seen in non-diabetic mice.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.